Table of Contents
ISRN Chemical Engineering
Volume 2013, Article ID 865618, 6 pages
http://dx.doi.org/10.1155/2013/865618
Research Article

Evaluation of Packed-Bed Reactor and Continuous Stirred Tank Reactor for the Production of Colchicine Derivatives

1Industrial Biotechnology Laboratory, University Institute of Engineering & Technology, M.D. University, Rohtak, Haryana 124001, India
2Gene Expression Laboratory, Department of Biosciences, Jamia Millia Islamia (A Central University), New Delhi, India
3RFCL, Okhla, New Delhi, India

Received 6 June 2013; Accepted 1 August 2013

Academic Editors: G. Bayramoglu, A. Brucato, I. Poulios, and I. Suelves

Copyright © 2013 Kashyap Kumar Dubey et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Bioconversion of colchicine into its pharmacologically active derivative 3-demethylated colchicine (3-DMC) mediated by P450BM3 enzyme is an economic and promising strategy for the production of this inexpensive and potent anticancer drug. Continuous stirred tank reactor (CSTR) and packed-bed reactor (PBR) of 3 L and 2 L total volumes were compared for the production of 3-demethylated colchicine (3-DMC) a colchicine derivative using Bacillus megaterium MTCC*420 under aerobic conditions. Statistical optimization technique was utilized with the most significant variables, that is, dissolved oxygen (DO), colchicine concentration, and process time for optimization. The validation of the model was performed by experiments on the predicted values in an individual run, and the optimum parameters were DO (~50%), colchicine concentration (7.5 g/L), and process time (39 h) resulted in a maximum bioconversion of 3-DMC 3.36 g/L. The PBR reactor achieved much higher productivity (6.58 g/L/h) as reported by earlier researchers. This is the first report on the use of PBR for bioconversion of colchicine.